ExCEEd Orphan s.r.o., a Czech based multinational company providing full business solutions in CEE region, announces new organizational structure and related appointments effective July 1st, 2020:
Jiri Hermanek, PhD, MBA, a founding partner of ExCEEd Orphan s.r.o., has been appointed as Chief Executive Officer of ExCEEd Orphan s.r.o. Jiri will be responsible for all aspects of growing ExCEEd Orphan business in the CEE region. Jiri is a successful BioPharma executive with a scientific background and extensive experience in managing CEE region over the past 15 years for multiple pharmaceutical companies, including Genzyme, Alexion, and Amicus Therapeutics. Jiri is a native Czech speaker and is fluent in English and Russian.
Libor Fronek, a founding partner of ExCEEd Orphan s.r.o., has been appointed as General Manager Czech Republic, Slovakia, and Poland. Libor is a successful BioPharma manager with extensive experience overseeing and managing the CEE orphan drugs market over the past 10 years for multiple pharmaceutical companies, including Cephalon, Alexion and Orphan Europe. Libor is a Czech native speaker and is fluent in English and Polish.
Neven Kolaric, MD, a founding partner of ExCEEd Orphan s.r.o., has been appointed as General Manager of newly created subsidiary ExCEEd Orphan Distribution d.o.o. In addition to this role, Neven will manage ExCEEd Orphan s.r.o. business in Croatia, Bulgaria, and North Macedonia. Neven s an experienced pharmaceutical industry professional with medical background, and extensive experience in rare diseases and orphan drugs, having worked with various companies, including Octapharma, Alexion and Orphan Europe. He is a native Croatian speaker, fluent in English and Russian.
Srdjan Simic, DVM,a founding partner of ExCEEd Orphan s.r.o., has been appointed as General Manager Slovenia and Serbia. Srdjan is an experienced BioPharma manager with a scientific background and proven track record in managing multiple markets within the CEE region over the past 10 years for several orphan drug companies, including Celgene, Takeda, Alexion, and Orphan Europe. Srdjan is a native Serbian speaker who is also fluent in English, German and Slovenian.
Tamas Vas, PharmD, a founding partner of ExCEEd Orphan s.r.o., has been appointed as General Manager Hungary and Romania. A pharmacist by education, Tamas has strong expertise and extensive experience in rare diseases in Hungary and the CEE region. Since 2002 he has worked for different orphan drug companies in the region, including Genzyme, Alexion, Santhera and Amicus Therapeutics. Tamas is a native Hungarian speaker, fluent in English.
Malgorzata Jurkiewicz, MD, has been appointed as Country Manager Poland. Malgorzata is a highly efficient professional with a proven track record of execution medical and commercial strategy in health care institutions and pharmaceutical industry including companies Schering AG, Cephalon, and Biogen. Malgorzata is native Polish speaker, fluent in English.
Eugenia Milicin, has been appointed as Country Manager Romania. Eugenia is a successful and efficient pharmaceutical professional with experience from companies like Johnson and Johnson, Schering-Plough, and Genzyme. She established Genzyme Romania and managed reimbursement and commercialization of multiple innovative and orphan products. Eugenia is a native Romanian speaker, fluent in English.